A randomised, double-masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age-related macular degeneration: Clinical trial design

Trials

Volumn 9, Issue , 2008, Pages

  Patel, Praveen J ^a   Bunce, C ^d   Tufail, Adnan ^a   da Cruz, L ^d   Dowler, J ^d   Egan, C ^d   Gregor, Z ^d   Hykin, P ^d   Mohamed, Q ^b   Johnston, R ^d   Majid, M ^c   Bailey, C ^d   Ikeji, F ^d   Richardson, M ^d   Waller, K ^d  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

^b CHELTENHAM GENERAL HOSPITAL   (United Kingdom)

^c BRISTOL EYE HOSPITAL   (United Kingdom)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; PLACEBO; RANIBIZUMAB; VERTEPORFIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HUMAN; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PHASE 4 CLINICAL TRIAL; PHOTODYNAMIC THERAPY; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY;

EID: 55649114212     PISSN: 17456215     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-9-56     Document Type: Article

References (15)

1. Klein R Klein BE Jensen SC Mares-Perlman JA Cruickshanks KJ Palta M Age-related maculopathy in a multiracial United States population: The National Health and Nutrition Examination Survey III Ophthalmology 1999, 106:1056-1065 10.1016/S0161-6420(99)90255-5 10366071
2. Friedman DS O'Colmain BJ Munoz B Tomany SC McCarty C de Jong PT Nemesure B Mitchell P Kempen J Prevalence of age-related macular degeneration in the United States Arch Ophthalmol 2004, 122:564-572 10.1001/ archopht.122.7.1019 15078675
3. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: Two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2 Am J Ophthalmol 2001, 131:541-560 10.1016/S0002-9394(01)00967-9 11336929
4. Gragoudas ES Adamis AP Cunningham ET Jr Feinsod M Guyer DR Pegaptanib for neovascular age-related macular degeneration N Engl J Med 2004, 351:2805-2816 10.1056/NEJMoa042760 15625332
5. Hurwitz H Fehrenbacher L Novotny W Cartwright T Hainsworth J Heim W Berlin J Baron A Griffing S Holmgren E et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 2004, 350:2335-2342 10.1056/NEJMoa032691 15175435
6. Avery RL Pieramici DJ Rabena MD Castellarin AA Nasir MA Giust MJ Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration Ophthalmology 2006, 113:363-372 10.1016/ j.ophtha.2005.11.019 16458968
7. Spaide RF Laud K Fine HF Klancnik JM Jr Meyerle CB Yannuzzi LA Sorenson J Slakter J Fisher YL Cooney MJ Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration Retina 2006, 26:383-390 10.1097/00006982-200604000-00001 16603955
8. Rosenfeld PJ Brown DM Heier JS Boyer DS Kaiser PK Chung CY Kim RY Ranibizumab for neovascular age-related macular degeneration N Engl J Med 2006, 355:1419-1431 10.1056/NEJMoa054481 17021318
9. Brown DM Kaiser PK Michels M Soubrane G Heier JS Kim RY Sy JP Schneider S Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 2006, 355:1432-1444 10.1056/NEJMoa062655 17021319
10. Costa RA Jorge R Calucci D Cardillo JA Melo LA Jr Scott IU Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): Results of a phase 1 dose-escalation study Invest Ophthalmol Vis Sci 2006, 47:4569-4578 10.1167/iovs.06-0433 17003454
11. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: One-year results of 2 randomized clinical trials-TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group Arch Ophthalmol 1999, 117:1329-1345 10532441
12. Csaky KG Richman EA Ferris FL 3rd Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium Invest Ophthalmol Vis Sci 2008, 49:479-489 10.1167/iovs.07-1132 18234989
13. Pelli DG Robson JG Wilkins AJ The design of a new letter chart for measuring contrast sensitivity. [abstract] Clin Vis Sci 1998, 2:187
14. Mansfield JS Ahn SJ Legge GE Luebker A A new reading acuity chart for normal and low vision Ophthalmic and Visual Optics/Noninvasive Assessment of the Visual System Technical Digest Washington, DC: Optical Society of America 1993, 232-235
15. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration BMJ 1994, 308:81-106 2539220 8298418